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type 2 diabetes mellitusWorldwide, both underdiagnosis and undertreatment leave many patients exposed to long periods of
hyperglycemia and contribute to irreversible diabetes complications. Early glucose control reduces the risk of
both macrovascular and microvascular complications, while tight control late in diabetes has little or no
macrovascular beneﬁt. Insulin therapy offers the most potent antihyperglycemic effect of all diabetes agents,
and has a unique ability to induce diabetes remission when used to normalize glycemia in newly diagnosed
patients. When used as a second-line therapy, basal insulin is more likely to safely and durably maintain A1C
levels ≤7% than when insulin treatment is delayed. The use of basal insulin analogs is associated with a
reduced risk of hypoglycemia and weight gain compared to NPH insulin and pre-mixed insulin. Patient self-
titration algorithms can improve glucose control while decreasing the burden on ofﬁce staff. Finally, recent
data suggest that addition of incretin agents to basal insulin may improve glycemic control with very little, if
any increased risk of hypoglycemia or weight gain.eived honoraria for consulting
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Preventing diabetic complications in the growing population of
people with diabetes depends ﬁrst on improving the rate of diagnosis.
Most diabetes agencies in the world recommend similar diagnostic
criteria based on the fasting plasma glucose (FPG; ≤126 mg/dL) and
2-hour oral glucose tolerance test (OGTT; ≤200 mg/dL), but so far
only the American Diabetes Association (ADA) recommends using the
A1C test for diagnosis (Association AD, 2013; Force IDFcGT, 2012).
Despite some challenges and controversies (lack of availability and/or
standardization of the A1C assay in some areas and reliability of A1C
results in patients with hemoglobinopathies and other conditions),
the A1C test can be a convenient and useful tool for screening because
patients' glucose levels can be tested in a nonfasting state (Association
AD, 2013). Regardless of the diagnostic method used (and clinicians
should make this choice according to their own preferences), at-risk
populations should be screened on a regular basis, because prompt
diagnosis and initiation of treatment are essential for preventing
diabetic complications.1.1. Undertreatment
Unfortunately, among the diagnosed, undertreatment prevails
throughout the world, where as many as one-half to two-thirds of
patientsdonothaveanA1Cb7% (Ali et al., 2013).According todata from
the 2010National Health and Nutrition Examination Survey (NHANES),
only 52% of patients in the U.S. have A1C levels b7%,while 13% have A1C
levels N9% (Ali et al., 2013). A 2009 study by the International Diabetes
ManagementPractice Study (IDMPS) found that inEasternEurope, Latin
America, and Asia, only 36% of patients with type 2 diabetes (and even
fewerwith type 1) had ever had their A1Cmeasured. Of those, only 36%
had an A1C b7% (Chan, Gagliardino, Baik, et al., 2009).
Nevertheless, various studies across the globe suggest that there
has been a reduction in the rate of diabetes-related amputations
(Association AD, 2013). In the U.S., the incidence of microalbuminuria
has declined, and end-stage renal disease has leveled off in recent
years, while the number of patients at severe risk of coronary heart
disease has declined. These ﬁgures emphasize the importance of
intensive glucose control for reducing the risk of microvascular
complications, which can have a dramatic impact on morbidity and
mortality (Lopez Stewart et al., 2007).
In order to achieve glycemic targets it is more practical and perhaps
more effective to ﬁrst reduce the fasting glucose. Control of fasting
glucose is necessary to achieve A1C levels close to 7%, because of the
relative contributions of fasting and postprandial glucose to overall
glycemia (Riddle, Umpierrez, DiGenio, Zhou, & Rosenstock, 2011;
Woerle, Neumann, Zschau, et al., 2007). At levels much greater than
7%, fasting glucose is the important determinant of A1C, whereas
postprandial glucose may becomemore important around 7%—a level of
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well as postprandial glucose contributes tomacrovascular disease. Above
approximately 100 mg/dL, rising fasting glucose is associated with an
increase in vascular death and coronary heart disease; this relationship is
almost linear once fasting glucose passes into the diabetic range (Sarwar,
Gao, Seshasai, et al., 2010; Seshasai, Kaptoge, Thompson, et al., 2011).
Targeting fastingglucose and lowering it to seewhetherwecaneliminate
or reduce this risk of cardiovascular disease are rational strategies.
Failure to start basal insulin is caused by multiple factors including
apprehension by patients and physicians, and fear of weight gain. In
insulin-naive patients with type 2 diabetes, psychological insulin
resistance (PIR) is not uncommon and contributes to unnecessarily
long delays for initiating insulin and consequently extending periods
of hyperglycemia (Polonsky & Jackson, 2004).
Clinicians as well may inadvertently inﬂuence patients' beliefs
about insulin through the use of such unfortunate terms as “oral agent
failure” (Polonsky & Jackson, 2004).
Another barrier to start insulin is the expectation of weight gain. In a
recent N2000 patients retrospective analysis of patient-level data with
insulin glargine it was reported that most patients had limited weight
change (+/−2.5 kg) after 24 weeks of insulin glargine (Shaefer et al.,
2014). The same analysis showed that younger patients were the ones
that gained more weight where as the elderly gained less weight and
had lower risk of hypoglycemia (Shaefer et al., 2014).
In 2010 a pooled analysis of randomized controlled trials of
patients with T2DM looked at weight and HbA1C changes comparing
insulin glargine and detemir which showed similar weight gain of
2.5 kg vs 1.7 kg respectively (Dailey, Admane, Mercier, & Owens,
2010). Using ﬁndings such as this one can help guide the physicians
on informing patients of realistic expectations about weight when
starting basal insulin and redirect the emphasis to basal insulin impact
on improvement of glycemic control rather than weight changes.
1.2. The legacy effect: early vs late glycemic control and complications risk
Glycemic goals should be determined by individual patients'
duration of disease, comorbidities, and other risk factors (Inzucchi,
Bergenstal, Buse, et al., 2012; Ismail-Beigi et al., 2011). Aggressive A1C
lowering in individuals with advanced type 2 diabetes only modestly
reduces macrovascular complications and poses added risk for these
patients (Inzucchi et al., 2012; Skyler, Bergenstal, Bonow, et al., 2009).
However, data suggest that there may be beneﬁt without such risk for
intensive glucose lowering in patients with early type 2 diabetes. In
these patients, reducing glucose to near-normal levels is essential for
long-term control of macrovascular risk, as shown by long-term
follow-up of the United Kingdom Prospective Diabetes Study
(UKPDS). Early control of glucose in the UKPDS had a sustained
beneﬁt on macrovascular risk, even when glycemic control deterio-
rated later. UKPDS participants had few or no complications at study
entry, and their FPG and A1C levels were kept low for the intervention
phase of the study, which lasted approximately 10 years. After that
point, glucose levels rose during the post-trial monitoring phase, but a
clear macrovascular beneﬁt remained (Chan et al., 2009).
The concept of the legacy effect emerged from these results andwas
supported by data from the opposite end of the diabetes spectrum,
which showed that uncontrolled glycemia from the beginning of
diabetes onset leads to complications that are irreversible (Del Prato,
2009; Gerstein, Miller, Byington, et al., 2008; Holman, Paul, Bethel,
Matthews, & Neil, 2008). In the Action to Control Cardiovascular Risk in
Diabetes (ACCORD), Veterans Affairs Diabetes Trial (VADT), and Action
in Diabetes and Vascular Disease: Preterax and Diamicron MR
Controlled Evaluation (ADVANCE) studies, participants had a long
duration of type 2 diabetes (8–12 years) and as well as existing
cardiovascular complications and baseline A1C levels between 8.0% and
9.4% (Duckworth, Abraira, Moritz, et al., 2009; Gerstein et al., 2008;
Patel, MacMahon, Chalmers, et al., 2008). All of these studies clearlydemonstrated that late intervention does little to prevent macrovas-
cular disease or stop its progression, probably because once complica-
tions set in, they are irreversible and frequently continue to develop
through activation of their own biochemical processes and pathways,
whichmaynot be reversedby instituting improvedglycemic control at a
late stage (Brownlee, 2001;Rolo&Palmeira, 2006;Nishikawa, Edelstein,
& Brownlee, 2000). Thus, the “bad legacy” of the ACCORD, VADT, and
ADVANCE patients' long-standing hyperglycemia undermined the
beneﬁts of later strict glucose control, and it is unrealistic to expect
that suddenly reducing blood glucose to normal after 10 or 15 years of
diabetes would reverse macrovascular complications.
The Outcome Reduction with an Initial Glargine Intervention
(ORIGIN) study also did not show a macrovascular beneﬁt in a
population somewhat different from that in previous studies. This
study compared the use of insulin glargine to maintain an FPG
≤95 mg/dL vs standard care in patients with either prediabetes or
newly diagnosed diabetes as well as established cardiovascular
disease or multiple risk factors for CVD, and reported a neutral effect
on cardiovascular outcomes. However, these results do not refute the
legacy effect concept. First, the beneﬁts of early glucose control may
take much longer to become apparent—the median follow-up of the
UKPDS post-trial monitoring was 17 years, compared with a median
of 6 years in ORIGIN (Gerstein, Bosch, Dagenais, et al., 2012; Holman
et al., 2008). Second, ORIGIN participants' cardiovascular risks were
severe—eligible patients had to have had a prior cardiovascular event
or evidence of kidney or vascular disease. Of more than 12,000 study
participants, 59% had a prior cardiovascular event, and thus this study
might be considered a secondary rather than a primary prevention
trial (Association AD, 2013). Given the extent of cardiovascular
comorbidities and the trial's relatively short follow-up period, ORIGIN
cannot provide any ﬁrm conclusions on the macrovascular beneﬁts of
intensive therapy in patients with early diabetes.
2. The rationale for earlier insulin initiation
The availability of increasing numbers of noninsulin antidiabetic
agents has fostered a reluctance to use insulin among physicians and
patients both, and surveys of clinicians have shown a persistent
misconception that insulin therapy canbedelayed indeﬁnitely if patients
adhere to noninsulin regimens (Hayes, Fitzgerald, & Jacober, 2008;
Peyrot, Rubin, Lauritzen, et al., 2005). This failure to promptly advance
therapy exposes patients to excess glycemic burden (Brown, Nichols, &
Perry, 2004). A retrospective analysis of data fromprimary care practices
in Europe showed that between 2005 and 2010, the time from type 2
diabetes diagnosis to insulin initiation increased by approximately
2 years. During the same period, the percentage of patients with at least
1macrovascular complication increased (Kostev &Mergenthaler, 2011).
As discussed, once suchmacrovascular complications set in, they cannot
be reversed with tight glycemic control, regardless of treatment
(Duckworth et al., 2009; Gerstein et al., 2008; Patel et al., 2008).
In contrast, achieving good glycemic control sooner than later
signiﬁcantly reduces the risk of diabetic complications, and this may
include the use of insulin to achieve good control. As described earlier,
patients treated with insulin in the UKPDS experienced not only a
reduced risk of microvascular complications in the short term but also
of macrovascular disease during long-term follow-up (Anonymous,
1998a; Holman et al., 2008). In addition, the UKPDS showed that early
addition of insulin to oral therapy reduced the risk of complications
(Wright, Burden, Paisey, Cull, & Holman, 2002).
Another concern with insulin is the incidence of hypoglycemic
episodes; the UKPDS showed that the risk of major hypoglycemic
episodes was not increased with the early addition of insulin to
sulfonylurea therapy (Wright et al., 2002).
Insulin therapymay also slow or even halt diabetes progression. In
patients with newly diagnosed type 2 diabetes, several small-scale
studies have demonstrated that short term intensive insulin
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induce disease remission (deﬁned by normal glucose levels) for up to
2 years (Chen et al., 2008; Ilkova, Glaser, Tunckale, Bagriacik, & Cerasi,
1997; Li, Xu, Liao, et al., 2004; McFarlane et al., 2001; Park & Choi,
2003; Xu, Li, Deng, Hao, & Weng, 2009). These ﬁndings were
substantiated by a recent study comparing intensive insulin therapy
with oral antidiabetic agents in 382 newly diagnosed patients. Study
participants had baseline A1C levels of 9.5% to 9.8% and were
randomly assigned to oral agents, multiple daily insulin injections,
or insulin pump therapy with the goal or rapid normalization of
glucose values within 2 weeks. Pharmacologic treatment was stopped
after normoglycemia (deﬁned as FPG b126 mg/dL or a 2-hour
postprandial glucose [PPG] b180 mg/dL) had been maintained for
2 weeks, and all patients followed a diet and exercise regimen
thereafter. Overall, 92% of patients achieved nondiabetic glucose
levels during the intervention period. After 1 year, the percentage of
patients retaining normoglycemia declined in all groups, but was
signiﬁcantly higher among insulin patients: 51% of those treated with
an insulin pump, 45% receiving multiple daily insulin injections, and
27% receiving oral agents maintained normoglycemia without
pharmacologic therapy (P = 0.0012 for both forms of insulin vs oral
agents). The acute insulin response also improved in all treatment
groups during the intervention period, but after 1 year, the insulin
response was maintained in the insulin groups but declined
signiﬁcantly in the oral therapy group (P b 0.0001). Patients in the
CSII group experienced the largest andmost durable improvements in
beta cell function (Weng, Li, Xu, et al., 2008). It is unclear whether
such “remission” of beta cell pathology can be achieved with less
intensive insulin therapy, and further research is needed in this area
to aid in translation of this beneﬁt to clinical practice.
The ORIGIN trial also demonstrated that insulin slows disease
progression in type 2 diabetes. Glargine reduced the risk of
progression to type 2 diabetes by 28% (P = 0.006) among 1426
patients with either IFG or IGT at the start of the trial. During the 6-
year follow-up period, 12% of prediabetic patients receiving glargine
and 20% of standard therapy patients developed diabetes (P b 0.001)
(Gerstein et al., 2012). These intriguing results suggest that intensive
insulin therapy at diagnosis may allow beta cells to rest and recover
some lost function.3. The choice of initial insulin
The ADA and EASD recommend starting insulin treatment with
basal insulin based on both the efﬁcacy and relative safety of this
approach (Inzucchi et al., 2012). Evidence for this strategy comes from
the 4 T Study, which compared basal, prandial, and biphasic insulins.
After 3 years, the endpoint A1C was similar in all 4 T study groups
(6.8%–7.1%; P = 0.28), and all 3 approaches reduced fasting glucose
to a comparable degree (P = 0.83). A prandial approach had the
greatest effect on postprandial glucose, and signiﬁcantly more
patients achieved an A1C b6.5% using prandial injections (45%; P =
0.006) or basal insulin (43%; P = 0.03) than biphasic insulin (32%).
However, in terms of adverse effects, the basal group experienced less
hypoglycemia and weight gain than the other approaches, while the
biphasic group had an intermediate incidence of hypoglycemia, and
the prandial group had the most hypoglycemic events. Patients
receiving prandial insulin gained the most weight (Holman, Farmer,
Davies, et al., 2009). These results are not surprising—prandial insulin
is hard to manage for both patients and clinicians owing to the
challenges of proper timing and appropriate matching of carbohy-
drate to insulin. When these factors do not align, more hypoglycemia
and compensatory eating can occur.
The 4 T results suggest that “good control” should be judged based
on not only A1C reductions but also on hypoglycemia risk. In choosing
a basal insulin, clinicians should consider the following key questions.3.1. How rapidly does the basal insulin improve glycemic control?
Both insulin glargine and insulin detemir are potent antihypergly-
cemic agents that rapidly reduce glycemia and can sustain target
glucose levels long-term. In the glargine clinical trials, baseline A1C
levels were generally N8.5%. A1C levels close to 7% were achieved
within 3 months and sustained for the duration of these studies
(6 months to a year) (Aschner, Chan, Owens, et al., 2012; Bretzel et al.,
2008; Gerstein et al., 2006; Riddle, Rosenstock, & Gerich, 2003;
Rosenstock et al., 2006; Swinnen, Dain, Aronson, et al., 2010; Yki-
Jarvinen, Kauppinen-Makelin, Tiikkainen, et al., 2006). Trials of basal
therapy with insulin detemir have shown similar robust A1C
reductions within 12 weeks (Hermansen et al., 2006; Hollander,
Raslova, Skjoth, Rastam, & Liutkus, 2011; Philis-Tsimikas et al., 2006).
Head-to-head studies of glargine and detemir have shown no
difference in A1C reductions and similar rates of hypoglycemia.
Weight gain has been signiﬁcantly lower with detemir than with
glargine in these studies, but the glargine doses needed to maintain
target glucose levels have been lower than the necessary detemir
doses (Swinnen et al., 2010; Rosenstock et al., 2008).
3.2. How well are the glycemic effects of basal insulin sustained over time?
As shown in the ORIGIN trial, basal insulin can maintain glucose at
target levels for long periods and can even halt diabetes progression
(Gerstein et al., 2012). A 3-year, open-label observational study with
insulin glargine use in every-day clinical practice demonstrated
sustained A1C reductions of 1.6% for 3 years; mean A1C remained
stable at 7.0% for the duration of that time (Fig. 1) (Schreiber, Ferlinz,
& Haak, 2008). In contrast, the UKPDS and ADOPT studies both
showed that diabetes progression could not be haltedwith oral agents
(Anonymous, 1998a, 1998b; Kahn, Haffner, Heise, et al., 2006).
3.3. What are the rates of symptomatic, severe, and nocturnal
hypoglycemia with basal insulin?
Rates of hypoglycemia are lower with the basal insulin analogs
glargine and detemir than with neutral protamine Hagedorn (NPH)
insulin (Hermansen et al., 2006; Philis-Tsimikas et al., 2006; Riddle
et al., 2003; Yki-Jarvinen et al., 2006), and may be lower still with
some long-acting insulin analogs under investigation (Bergenstal,
Rosenstock, Arakaki, et al., 2012; Garber, King, Del Prato, et al., 2012;
Zinman, Fulcher, Rao, et al., 2011). Looking forward to the near future
we will have even more choices of basal insulin which are already
showing good promise of lower rates of nocturnal hypoglycemia.
For example BEGIN trials in patients with type 2 diabetes showed
that the rates of severe hypoglycemia were low and occurred
signiﬁcantly less frequently with insulin degludec (Battise, 2013).
In the EDITION 1 trial, U-300 glargine was as effective as U-100
glargine but was associated with less risk of nocturnal hypoglycaemia
(Riddle et al., 2014). Finally, novel long acting insulin (LY2605541) was
compared to insulin glargine in a 12-week, randomized, open-label, phase
2 study which showed, that LY2605541 and glargine had comparable
glucose control and total hypoglycemia rates, but LY2605541 showed
reduced intraday variability, lower nocturnal hypoglycemia, and weight
loss relative to glargine (Bergenstal et al., 2012).
In a treat-to-target study of glargine vs NPH, symptomatic
hypoglycemia was reduced by 21% (P = 0.02) and nocturnal
hypoglycemia by 42% (P b 0.001). Severe hypoglycemia occurred in
2.5% of glargine patients and 1.8% of NPH patients (Riddle et al., 2003).
This ﬁnding may raise a question whether there is an advantage to
glargine; however the occurrence of six insulin glargine-associated
events in the evening, when the therapeutic effect of bedtime glargine
would be lowest, suggests that these events were in part due to the
sulfonylurea (Dailey, Strange, & Riddle, 2009). Also, given that the
baseline HbA1Cwas lower in this study than inmost other studies and
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reaching target HbA1C without an episode of nocturnal hypoglycae-
mia), treatment success was achieved by more subjects with glargine
33.2% than with NPH 26.7% (Riddle et al., 2003). Furthermore, the goal
for FBG ≤120 was reached by glargine by 55.3% of patient without
documented nocturnal hypoglycemia compared with NPH at 41.6%
(Riddle et al., 2003). This study demonstrated that rates of daytime
hypoglycemia were reassuringly low, showing that the reduction of
nocturnal hypoglycemia with glargine did not come at the expense of
more hypoglycemia throughout the day (Riddle et al., 2003). For all
reported events, rates of nocturnal hypoglycaemia with glargine versus
NPH were 3.1% and 5.5% respectively (P b 0.001) (Riddle et al., 2003).
In this context, an analysis of a 5 year study comparing glargine
and NPH evaluated HbA1c-adjusted hypoglycemia risk with glargine
vs NPH and conﬁrmed that glargine provides sustained, clinically
meaningful reduction in risk of hypoglycemia compared with NPH in
patients with T2DM (Rosenstock et al., 2014). The number needed to
harm by choosing NPH over glargine was 25 in terms of causing
hypoglycemia (Rosenstock, Fonseca, Schinzel, et al., 2014).
Another treat-to-target study showed that detemir was associated
with a 47% reduction in any hypoglycemia and a 55% decrease in
nocturnal hypoglycemia compared with NPH (P b 0.001 for both).
Major hypoglycemia occurred at rates of 0.01 event per patient per
year for detemir and 0.08 events per patient per year for NPH
(Hermansen et al., 2006). In head-to-head studies of glargine and
detemir added to oral agents, symptomatic hypoglycemia episodes
occurred at rates of 6–9 events per patient per year, with 1–3
nocturnal events per patient per year, without signiﬁcant differences
between treatment groups (Rosenstock et al., 2008; Swinnen et al.,
2010). Based on these ﬁndings, basal insulin analogs are preferred
over NPH in the ADA and EASD treatment recommendations (Inzucchi
et al., 2012).
3.4. How satisﬁed are patients with basal insulin, and what are the
quality of life data?
Users of basal insulin analogs report greater satisfaction than
patients treated with other agents (Polonsky, Traylor, Wei, et al.,
2012; Swinnen et al., 2010). In a pooled analysis of glargine clinical
trial results, mean improvements in Diabetes Treatment Satisfaction
Questionnaire change (DTSQc) were signiﬁcantly greater with
glargine than with comparators, which included oral antidiabetic
drugs, NPH, and premixed insulin (mean scores 13.5 vs. 12.1,
P b 0.001). Treatment satisfaction was associated with positive
changes in A1C and FPG (P b 0.001) as well as a minimally negative
impact on weight (P = 0.02) (Polonsky et al., 2012). DTSQs and
DTSQc scores in a head-to-head study of glargine and detemir showed
that patientswere signiﬁcantlymore satisﬁedwith glargine treatmentFig. 1. Sustained A1C reductions with basal insulin in a prospective, observationvs detemir, despite lesser weight gain with detemir. The authors of
this study speculated that this might be because of the lower glargine
doses (Swinnen et al., 2010).
4. Implications for clinical practice
4.1. Minimizing risk of hypoglycemia
Glycemic control involves not only reducing A1C but also
minimizing the risk of hypoglycemia, and earlier introduction of
basal insulin can achieve both goals. In a pooled analysis of 11
prospective clinical trials in which glargine was added tometformin, a
sulfonylurea, or both, A1C reductions were signiﬁcantly greater when
glargine was added to oral monotherapy instead of dual therapy
(Fig. 2). Hypoglycemia rates were also lower with a single oral agent
vs two oral agents, even when the single agent was a sulfonylurea.
Symptomatic hypoglycemia occurred at rates of 1.81, 4.88, and 7.30
events per patient–year when glarginewas added tometformin alone,
sulfonylurea alone, and both agents, respectively, while rates of severe
hypoglycemia were 0.0, 0.02, and 0.06 events per patient–year. In the
analysis of glargine added to 1 vs 2 agents, 4.05 vs 7.18 symptomatic
hypoglycemia events per patient–year occurred (P = 0.0009) (Fon-
seca, Gill, Zhou, & Leahy, 2011).
Another meta-analysis of pooled data from studies of basal insulin
added to metformin showed that any hypoglycemia (deﬁned as an
A1C b70 mg/dL) occurred at a rate of only 3 episodes per patient per
year, while nocturnal hypoglycemia occurred less than once a year,
and severe hypoglycemia requiring another person's assistance was
extremely rare, occurring at a rate of only 0.07 events per patient per
year (Bergenstal, 2012).
These results make a good case for using basal insulin earlier in the
paradigm of T2DM treatment when patients have less disease
progression (as is generally the case for patients receiving a single
antidiabetic agent). The beneﬁts of using basal insulin as a second-line
agent, which is advocated in the 2012 ADA/EASD recommendations
(Inzucchi et al., 2012), are demonstrated in the Evaluation of Insulin
Glargine Versus Sitagliptin in Insulin-naive Patients (EASIE) trial
(Aschner et al., 2012). In this study, patients already receiving
metformin with poorly controlled type 2 diabetes (mean baseline
A1C 8.5% and elevated fasting and postprandial glucose levels) were
randomized to receive glargine once a day or sitagliptin 100 mg a day
for 24 weeks. Signiﬁcantly greater A1C reductions occurred with
glargine vs sitagliptin (1.7% vs 1.3%; P b 0.0001), and signiﬁcantly
more glargine patients met A1C targets of b7.0% (68% vs 42%;
P b 0.0001) and b6.5% (40% vs 17%; P b 0.0001). Glargine also had a
greater overall effect on glucose excursions than sitagliptin because
the insulin reduced not only the fasting glucose but the premeal
glucose. Thus, even though sitagliptin produced larger absoluteal trial of basal insulin use in real-life clinical practice (Arnolds et al., 2010).
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exposure by lowering the baseline of each mealtime excursion. As
might be expected, hypoglycemia rates were higher with glargine, but
overall rates were very low (4 events per patient–year), with less than
1 event per patient–year of nocturnal hypoglycemia and 0.03 events
per patient per year of severe hypoglycemia (Aschner et al., 2012).
4.2. Minimizing weight gain
In the UKPDS study, weight gain was signiﬁcantly higher in the
intensive group (mean 2.9 kg) than in the conventional group
(p b 0.001), and patients receiving insulin had a more pronounced
gain in weight (4.0 kg) than those assigned chlorpropamide (2.6 kg)
or glibenclamide (1.7 kg) (Sarwar et al., 2010). Although additional
insulin use is always concerning for weight gain, in the UKPDS the
early combination of sulfonylurea and insulin did not promote weight
gain as compared to patients allocated to therapy with insulin alone
(Wright et al., 2002).
Patients in the EASIE trial glargine group gained an average of
0.44 kg, while those in the sitagliptin group lost a mean of 1.08 kg, for
a treatment difference of 1.51 kg (P b 0.0001) (Aschner et al., 2012).
These results beg the question—what happens when an incretin agent
and basal insulin are combined? An ongoing extension of the EASIE
study will enhance our understanding of this issue, but we know from
other trials that incretin agents can neutralize insulin-associated
weight gain (or even reduce weight overall) while lowering A1C. To
date, studies of basal insulin with DPP-4 inhibitors plus metformin
have demonstrated A1C reductions of ~1.5%, with low rates of
hypoglycemia and little to no weight gain (Arnolds, Dellweg, Clair,
et al., 2010; Hollander et al., 2011). The GLP-1 receptor agonists may
offer even greater A1C-lowering and also the potential to nullify
insulin-induced weight gain, particularly when they are added to
optimally titrated basal insulin (Arnolds et al., 2010; Aronson, Riddle,
Home, et al., 2012; Buse, Bergenstal, Glass, et al., 2011; DeVries, Bain,
Rodbard, et al., 2012; Riddle, Forst, Aronson, et al., 2013). The newly
approved sodium glucose cotransporter 2 (SGLT2) inhibitor canagli-
ﬂozin may also decrease weight in insulin-treated patients (Yale,
Bakris, Cariou, et al., 2013). In clinical practice, such combinations
might be considered for patients who have inadequate glycemic
control and for whom the risk of hypoglycemia and/or weight gain are
a concern.
4.3. Basal insulin titration
Patient-driven titration of insulin is a growing trend that can
facilitate the introduction of insulin. The AT.LANTUS and Predictable
Results and Experience in Diabetes through Intensiﬁcation andFig. 2. Mean change in A1C from baseline (top of bar) to 24 weeks (bottom of bar)
when basal insulin is added to metformin, sulfonylurea, or both. P value shown for 3
bars on right is for comparison among all three groups (Gakidou, Mallinger, Abbott-
Klafter, et al., 2011).Control to Target: An International Variability Evaluation (PREDIC-
TIVE) studies both clearly showed that patients can safely and
effectively titrate their own basal insulin if given adequate instruc-
tions (Davies, Storms, Shutler, Bianchi-Biscay, & Gomis, 2005;
Meneghini, Koenen, Weng, & Selam, 2007). In the AT.LANTUS study,
patients using a self-titration algorithm signiﬁcantly reduced their
fasting glucose levels compared to patients using a physician-directed
algorithm (−62 vs−57 mg/dL; P b 0.001). Self-titrating patients also
experienced signiﬁcantly larger A1C reductions of−1.22% compared
with −1.08% (P b 0.001). Symptomatic hypoglycemia occurred at a
signiﬁcantly higher rate with the patient-driven algorithm, but
differences in the rates of severe and nocturnal hypoglycemia were
not statistically signiﬁcant. Finally, weight gain was similar in the 2
treatment groups (Davies et al., 2005).
In the PREDICTIVE study, patients self-titrating their insulin dose
likewise experienced signiﬁcantly greater A1C (−0.6% vs −0.5%;
P = 0.01) and FPG reductions (−34 vs −22 mg/dL; P b 0.0001)
compared to patients whose basal insulin doses were determined by a
physician. Mean body weight remained the same at 26 weeks in both
groups. Rates of overall hypoglycemia were higher among patients
self-titrating their insulin dose (6.44 events per patient per year) than
patients in the physician-directed group (4.95 events per patient per
year), but major hypoglycemic events were rare in both groups (0.26
events/patient/year for the patient-driven group and 0.20 events/
patient/year for the physician-driven group; P = 0.2395) (Meneghini
et al., 2007).4.4. Beyond fasting glucose: next steps for optimal glucose control
Despite the potency of basal insulin, its ultimate efﬁcacy is limited
by its potential for hypoglycemia. In treat-to-target trials of basal
insulin, mean endpoint A1C levels have ranged between 6.8% and
7.2%, and 30% to 50% of patients had an A1C N7% at the end of the
study (Bretzel et al., 2008; Hermansen et al., 2006; Rosenstock et al.,
2006). Further reductions in A1C are desirable, if they can be achieved
without increased risk of hypoglycemia or weight gain. Because the
incretin agents stimulate insulin secretion in a glucose-dependent
manner, adding them to basal insulin may reduce A1C to the ≤7%
threshold without increasing the risk of hypoglycemia or weight gain.
This strategy has been demonstrated with the short-acting GLP-1
receptor agonists exenatide and lixisenatide, which have a pro-
nounced effect on PPG. In these studies, mean endpoint A1Cs in the
combination therapy groups were 6.7% with exenatide plus glargine
and metformin and 7.0% with lixisenatide plus glargine and oral
agents (Buse et al., 2011; Riddle et al., 2013). Another study examined
the combination in the reverse order—detemir was added to
liraglutide and metformin in patients with suboptimal glycemic
control, achieving a mean endpoint A1C of 7.1% (DeVries et al., 2012).
A few recent studies have also examined the effect of longer acting
GLP-1 RAs in combination with insulin. For example, adding once
weekly albiglutide to basal insulin led to equal reduction in A1c as
adding 3 prandial insulin injections daily, with less weight gain and
hypoglycemia and considerably less patient burden in terms of
number of injections (Rosenstock, Fonseca, Gross, et al., 2014).
Furthermore, data have also been presented on the efﬁcacy of ﬁxed
dose combinations of lirglutide and degludec (ideglira) and lixisena-
tide and glargine (Buse, Vilsbøll, et al., 2013; Buse, Woo, et al., 2013;
Rosenstock, Silverstre, Souhami, Zhou, & Fonseca, 2014). Availability
of such ﬁxed injection combinations may well lead to better glycemic
control with less weight gain and hypoglycemia compared to just
staring insulin alone.
Because of differences in A1C lowering, weight effects, and relative
impact on FPG and PPG among and within the incretin classes,
additional studies are needed to expand our understanding of the
beneﬁts these agents in combination with basal insulin.
300 D. Lovre, V. Fonseca / Journal of Diabetes and Its Complications 29 (2015) 295–3015. Conclusions
Early combination of basal insulin with metformin is associated
with less hypoglycemia than adding basal insulin to 2 agents, with
relatively low rates of weight gain. If and when glucose control
deteriorates in patients receiving basal insulin and metformin, the
incretin agents may be considered. Combining these agents with
insulin does not greatly increase the risk of hypoglycemia. Further-
more, they are unlikely to lead to weight gain and may even reduce
patients' weight. For patientswhose fasting glucose levels are optimal,
consideration should be given to agents that have a primary effect on
PPG, such as the short-acting GLP-1 receptor agonists.
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